CAJ | 학술논문

目的：观察紫杉醇腹腔内灌注对治疗恶性腹水的近期疗效。方法18例恶性腹水患者随机、双盲分为紫杉醇组和顺铂组，采用对照研究，分别于腹腔积液尽量排净后，给予腹腔内灌注紫杉醇或顺铂。每周1次，连续3周。结果紫杉醇组临床总有效率为88.9%，顺铂组临床总有效率为55.6%，两组相比差异具有统计学意义(P<0.05)。紫杉醇组生活质量改善较顺铂组明显，两组药物不良反应差异无统计学意义(P>0.05)。结论腹腔内灌注紫杉醇治疗恶性腹水近期疗效较好，操作简单方便、不良反应少，是一种前景较好的治疗方法。
목적：관찰자삼순복강내관주대치료악성복수적근기료효。방법18례악성복수환자수궤、쌍맹분위자삼순조화순박조，채용대조연구，분별우복강적액진량배정후，급여복강내관주자삼순혹순박。매주1차，련속3주。결과자삼순조림상총유효솔위88.9%，순박조림상총유효솔위55.6%，량조상비차이구유통계학의의(P<0.05)。자삼순조생활질량개선교순박조명현，량조약물불량반응차이무통계학의의(P>0.05)。결론복강내관주자삼순치료악성복수근기료효교호，조작간단방편、불량반응소，시일충전경교호적치료방법。
Objective To observe the the recent curative effect of taxol intraperitoneal perfusion of for the treatment of malignant ascites. Methods 18 patients with malignant ascites in random and double-blind are divided into paclitaxel and cisplatin groups, with contrast study, in the abdominal cavity effusion complete as far as possible, worked in intraperitoneal perfusion paclitaxel and cisplatin respectively. Once a week, for three weeks. Results Paclitaxel group clinical total effective rate was 88.9%, and cisplatin group clinical total effective rate was 55.6%. Comparison between two groups has significant difference (P<0.05). Paclitaxel quality of life for improvement was more obvious than the cisplatin. No distinct difference between the two groups of drug on adverse reactions. Conclusion Intraperitoneal perfusion with paclitaxel in the mid of curing malignant ascites, the near future curative effect is good, and easy and convenient operation, less side effects and is a good treatment for prospect.